CLC Calculus Vct Plc

RNS Number:2903C
AIM
17 August 2007


    ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR
                                                COMPANIES ("AIM RULES")

COMPANY NAME:
Clinical Computing plc


COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :
2 Kew Bridge Road

Brentford

Middlesex TW8 0JF


COUNTRY OF INCORPORATION:
England and Wales


COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:
www.ccl.com


COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS
INVESTING STRATEGY).  IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE
STATED:
Development of clinical information management software to facilitate the treatment of chronic disease (currently
Chronic Kidney Disease).  Main countries of operation are the UK, USA and Australia.


DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known,
number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held
as treasury shares):
33,110,361 ordinary shares of 1 penny each

No restrictions as to transfer


CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:
Capital to be raised on Admission: Nil

Anticipated market capitalisation: #1.37 million


PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:
36.8%


DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE
OR WILL BE ADMITTED OR TRADED:
Currently admitted to the Official List of the UKLA and to trading on the London Stock Exchange's market for listed
securities, however application has been made for the cancellation of this listing, which is expected to take place at
8.00am on 17 September 2007 simultaneously with admission to AIM.


FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or
including any other name by which each is known):
Howard Edward Kitchner, Non-Executive Chairman

Joseph George Marlovits (known as Joe), Chief Executive Officer

Professor Stanton Peter Newman (known as Stan), Non-Executive Director


FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND
AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Name                                               Shares held                 Percentage holding
Michael Gordon                                     5,811,800                   17.55
Howard Edward Kitchner*                            3,164,996                   9.56
David Altschuler*                                  2,881,496                   8.70
Global Asset Management Limited                    2,019,765                   6.10
James Conrad Venn                                  1,807,900                   5.46
Neil Mendoza                                       1,150,000                   3.47



* - In addition to the shareholdings shown above, 203,008 ordinary shares are registered in the name of South Quay
Plaza Retirement Fund, in which Howard Kitchner and David Altschuler are beneficially interested


NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:
In the twelve months prior to the date of this notification:

-          Baker Tilly Corporate Finance LLP has received (or entered into agreements to receive) fees of, in
aggregate, #24,000 for the provision of services in connection with the Company's delisting from the official list and
admission to AIM

-          Baker Tilly has received fees of, in aggregate, approximately #33,700 for the provision of audit, tax and
advisory services

-          Baker Tilly UK Audit LLP (who were appointed as successor auditors to Baker Tilly with effect from 1 April
2007) has received fees of, in aggregate, approximately #10,000 for the provision of audit services

-          Baker Tilly Tax and Advisory Services LLP (who were appointed as successor advisers to Baker Tilly with
effect from 1 April 2007) has received fees of, in aggregate, approximately #10,500 for the provision of tax and
advisory services

-          City Financial Associates Limited has received (or entered into agreements to receive) fees of, in
aggregate, #35,000 for the provision of corporate finance advice in connectionwith the proposed delisting from the
official list and admission to AIM, and an annual fee of a further #20,000 to act as nominated adviser to the Company
following its Admission to AIM

-          Berwin Leighton Paisner LLP, the Company's lawyers, has received (or entered into agreements to receive)
fees of, in aggregate, approximately #42,000 for the provision of legal advice.


(i)                  ANTICIPATED ACCOUNTING REFERENCE DATE

(ii)                DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED

(iii)               DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:
(i)         31 December

(ii)        No admission document has been prepared as Clinical Computing plc is a Quoted Applicant

(iii)       Half yearly report for the period to 30 June 2007, by 30 September 2007

            Annual accounts for the year to 31 December 2007, by 30 June 2008

            Half yearly report for the period to 30 June 2008, by 30 September 2008


EXPECTED ADMISSION DATE:
17 September 2007


NAME AND ADDRESS OF NOMINATED ADVISER:
City Financial Associates Limited

46 Worship Street

London EC2A 2EA


NAME AND ADDRESS OF BROKER:
TBC


OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL
BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS
SECURITIES:
n/a - Quoted Applicant


DATE OF NOTIFICATION:
16 August 2007


NEW/ UPDATE:
New


QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING:

THE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED:
UKLA Official List


THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED:
17 February 1994


CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS ADHERED TO ANY LEGAL AND REGULATORY
REQUIREMENTS INVOLVED IN HAVING ITS SECURITIES TRADED UPON SUCH A MARKET OR DETAILS OF WHERE THERE HAS BEEN ANY BREACH:
The Company confirms that, following due and careful enquiry, it has adhered to the legal and regulatory requirements
involved in having its securities traded on the London Stock Exchange.


AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE APPLICANT HAS MADE PUBLIC OVER THE LAST
TWO YEARS (IN CONSEQUENCE OF HAVING ITS SECURITIES SO TRADED) ARE AVAILABLE:
www.ccl.com


DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS
INVESTING STRATEGY:
As the US and UK populations continue to age, management of chronic diseases will place increasing stress on the
healthcare services. The Group's strategy is to establish its Clinical Vision product as an interactive electronic
medical record solution for chronic disease. The Company's initial focus is the Chronic Kidney Disease market where it
has been an industry leader in End Stage Renal Disease. The increase of chronic diseases is forcing fundamental changes
to the electronic healthcare record market; whereby better integration and more timely clinical information sharing
between primary and secondary care providers will result in implementing preventative actions sooner in the care
process thereby reducing the overall cost of care. New care practices will evolve with respect to chronic diseases, and
information systems will be needed to deliver information to more users across a healthcare system, including the
patients.



To meet this challenge the Company is now developing and quality assurance testing its latest technology, Clinical
Vision Web. This technology release will provide the Company with the ability to support its strategic goals of
delivering chronic disease solutions supporting early identification and complete life cycle management of chronic
disease.
A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THE APPLICANT, WHICH HAS OCCURRED SINCE THE
END OF THE LAST FINANCIAL PERIOD FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED:
Save as announced in the AGM statement on 29 June 2007 and/or disclosed in the Company's circular to shareholders dated
23 July 2007, there has been no significant change in the financial or trading position of the Company since 31
December 2006, being the end of the last financial period for which audited financial statements have been published.


A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT THE WORKING CAPITAL AVAILABLE TO IT OR
ITS GROUP WILL BE INSUFFICIENT FOR AT LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION:
The directors of the Company have no reason to believe that the Group's working capital will be insufficient for at
least twelve months from the date of its admission to AIM.


DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES:
None.


A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S SECURITIES:
The Company's ordinary shares will continue to settle through CREST and in certificated form.


A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S SECURITIES:
The Articles of Association of the Company are to be found on the company's website at www.ccl.com


INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC:
N/A


A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT AND ACCOUNTS WHICH MUST HAVE A FINANCIAL
YEAR END NOT MORE THEN NINE MONTHS PRIOR TO ADMISSION AND INTERIM RESULTS WHERE APPLICABLE.  THE ACCOUNTS MUST BE
PREPARED IN ACCORDANCE WITH ACCOUNTING STANDARDS PERMISSIBLE UNDER AIM RULE 19:
www.ccl.com/corporate/reports.asp


THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TREASURY:
None






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PAAOKAKNOBKDBFD

Calculus Vct (LSE:CLC)
Historical Stock Chart
From Jun 2024 to Jul 2024

Calculus Vct (LSE:CLC)
Historical Stock Chart
From Jul 2023 to Jul 2024